Today: 7 February 2026
Subscribe
Browse Category

Earnings Reports News 6 February 2026

CoreWeave stock price jumps 18% as AI-spending trade rebounds; CRWV earnings date set

CoreWeave stock price jumps 18% as AI-spending trade rebounds; CRWV earnings date set

CoreWeave shares jumped 18.3% to $88.31 Friday, rebounding after two days of steep losses. Trading volume hit 27.7 million by 3 p.m. EST. The surge followed Amazon’s $200 billion data center spending plan and Nvidia’s recent $2 billion investment in CoreWeave. The company also launched its first brand campaign and unveiled a new customer testing lab.
6 February 2026
··
Impinj stock dives 24% after outlook whiffs; Evercore slashes rating on PI

Impinj stock dives 24% after outlook whiffs; Evercore slashes rating on PI

Impinj shares fell 24.3% to $116.46 Friday after the company forecast a sharp first-quarter slowdown, citing inventory burn-down in logistics and weaker systems demand. Evercore ISI downgraded the stock and cut its price target to $112. Fourth-quarter revenue came in at $92.8 million, with first-quarter guidance of $71–$74 million. The stock hit an intraday low of $105.
6 February 2026
··
Estee Lauder stock rebounds after brutal earnings selloff as Citi upgrade shifts focus to tariffs

Estee Lauder stock rebounds after brutal earnings selloff as Citi upgrade shifts focus to tariffs

Estee Lauder shares rose about 4% to $100.58 on Friday, recovering part of Thursday’s post-earnings drop. Citi upgraded the stock to “buy,” citing elevated expectations and travel retail disruptions as key factors in the selloff. The company reported fiscal Q2 net sales up 6% to $4.23 billion and reiterated a $100 million tariff hit to annual profit. U.S. demand and tariffs remain major concerns.
6 February 2026
··
VeriSign stock dives nearly 10% after outlook, costs take the shine off results

VeriSign stock dives nearly 10% after outlook, costs take the shine off results

VeriSign shares dropped nearly 10% Friday after its quarterly report, underperforming a rising market. The company raised its dividend and maintained heavy buybacks, but 2026 guidance and .com pricing limits drew scrutiny. Fourth-quarter revenue reached $425 million with net income of $206 million. Post-hearing briefs in the .web arbitration are expected in the first half of 2026.
6 February 2026
··
Qualys stock slides nearly 13% after Q4 beat as 2026 outlook cools the mood

Qualys stock slides nearly 13% after Q4 beat as 2026 outlook cools the mood

Qualys shares dropped 12.7% to $111.62 Friday after the company forecast 2026 revenue growth of 7% to 8%, below last year’s 10%. The cybersecurity firm reported fourth-quarter revenue of $175.3 million and raised its share buyback program by $200 million. RBC and Truist trimmed price targets. CEO Sumedh Thakar received performance shares, with some withheld for taxes.
6 February 2026
···
Cisco stock pops near a fresh high as UBS sticks with Buy ahead of Feb. 11 earnings

Cisco stock pops near a fresh high as UBS sticks with Buy ahead of Feb. 11 earnings

Cisco shares rose 2.4% to $84.32 Friday, nearing a record high ahead of its Feb. 11 earnings report. UBS reaffirmed its Buy rating and $90 target, citing stable enterprise demand and expected revenue above $15.05 billion. Investors are watching for updates on AI-driven orders and network spending. The earnings release coincides with key U.S. jobs and inflation data.
6 February 2026
···
ALGN stock jumps again as Align Technology rides Invisalign earnings beat and fresh analyst targets

ALGN stock jumps again as Align Technology rides Invisalign earnings beat and fresh analyst targets

Align Technology shares rose about 4% to $182.70 by midday Friday, following a strong earnings report and record clear-aligner shipments. The company posted Q4 revenue of $1.05 billion and non-GAAP earnings of $3.29 per share, with 676,900 cases shipped. Align forecast Q1 revenue between $1.01 billion and $1.03 billion. The stock jumped 11% in the previous session.
6 February 2026
····
AbbVie stock rises as investors re-rank Rinvoq and Skyrizi after earnings jolt

AbbVie stock rises as investors re-rank Rinvoq and Skyrizi after earnings jolt

AbbVie shares climbed 2% to $223.45 in midday trading Friday after a volatile week. The move followed a quarterly report showing fourth-quarter net revenues up 10% to $16.62 billion and adjusted profit of $2.71 per share. Humira sales dropped 25.9% as biosimilar competition increased, while Skyrizi and Rinvoq posted gains. The company also announced new regulatory approvals and licensing deals.
6 February 2026
···
1 … 3 4 5 6 7 … 337

Stock Market Today

Broadcom Stock Gets a Google AI Spend Lift as Jefferies Sees 60% Upside

Broadcom Stock Gets a Google AI Spend Lift as Jefferies Sees 60% Upside

7 February 2026
Google raised its 2026 capital expenditure forecast to $175 billion–$185 billion, with most spending expected on data-center chips. Broadcom shares rose about 2% after the announcement, while Nvidia and AMD slipped. Jefferies reiterated a buy rating on Broadcom, maintaining a $500 price target, implying a 62% upside from Wednesday’s close.
No $2,000 IRS stimulus check is coming in February 2026 — but Trump’s tariff-check talk keeps the rumors alive

No $2,000 IRS stimulus check is coming in February 2026 — but Trump’s tariff-check talk keeps the rumors alive

7 February 2026
The IRS has not announced new federal stimulus payments for February 2026, and Congress has not approved fresh checks. Trump told NBC he is considering $2,000 tariff rebate checks but has not committed, saying any payout would likely come later in 2026. The IRS warns taxpayers to ignore texts and emails about “stimulus payments” and verify notices through official channels.
Go toTop